Ensysce Biosciences Stock Cash Flow From Operations
| ENSC Stock | USD 0.43 0.16 27.12% |
Ensysce Biosciences fundamentals help investors to digest information that contributes to Ensysce Biosciences' financial success or failures. It also enables traders to predict the movement of Ensysce Stock. The fundamental analysis module provides a way to measure Ensysce Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Ensysce Biosciences stock.
Ensysce |
Ensysce Biosciences Company Cash Flow From Operations Analysis
Ensysce Biosciences' Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current Ensysce Biosciences Cash Flow From Operations | (10.78 M) |
Most of Ensysce Biosciences' fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Ensysce Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, Ensysce Biosciences has (10.78 Million) in Cash Flow From Operations. This is 102.04% lower than that of the Biotechnology sector and 117.24% lower than that of the Health Care industry. The cash flow from operations for all United States stocks is 101.11% higher than that of the company.
Ensysce Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Ensysce Biosciences' direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Ensysce Biosciences could also be used in its relative valuation, which is a method of valuing Ensysce Biosciences by comparing valuation metrics of similar companies.Ensysce Biosciences is currently under evaluation in cash flow from operations category among its peers.
Ensysce Fundamentals
| Return On Equity | -4.28 | ||||
| Return On Asset | -1.32 | ||||
| Operating Margin | (10.76) % | ||||
| Current Valuation | 4.65 M | ||||
| Shares Outstanding | 19.57 M | ||||
| Shares Owned By Insiders | 1.17 % | ||||
| Shares Owned By Institutions | 22.26 % | ||||
| Number Of Shares Shorted | 6.35 M | ||||
| Price To Book | 1.22 X | ||||
| Price To Sales | 5.85 X | ||||
| Revenue | 2.23 M | ||||
| Gross Profit | (1.16 M) | ||||
| EBITDA | (10.72 M) | ||||
| Net Income | (10.63 M) | ||||
| Cash And Equivalents | 3.15 M | ||||
| Cash Per Share | 0.10 X | ||||
| Total Debt | 854.7 K | ||||
| Debt To Equity | 6.91 % | ||||
| Current Ratio | 0.87 X | ||||
| Book Value Per Share | (0.10) X | ||||
| Cash Flow From Operations | (10.78 M) | ||||
| Short Ratio | 0.12 X | ||||
| Earnings Per Share | (1.94) X | ||||
| Target Price | 6.8 | ||||
| Beta | 0.64 | ||||
| Market Capitalization | 8.42 M | ||||
| Total Asset | 2.71 M | ||||
| Retained Earnings | (121.56 M) | ||||
| Working Capital | (1.04 M) | ||||
| Net Asset | 2.71 M |
About Ensysce Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Ensysce Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ensysce Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ensysce Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Ensysce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Ensysce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Ensysce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Ensysce Biosciences Stock:Check out Ensysce Biosciences Piotroski F Score and Ensysce Biosciences Altman Z Score analysis. For information on how to trade Ensysce Stock refer to our How to Trade Ensysce Stock guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ensysce Biosciences. If investors know Ensysce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ensysce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Ensysce Biosciences is measured differently than its book value, which is the value of Ensysce that is recorded on the company's balance sheet. Investors also form their own opinion of Ensysce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Ensysce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ensysce Biosciences' market value can be influenced by many factors that don't directly affect Ensysce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ensysce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ensysce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ensysce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.